An interventional study of WiSE CRT System in Heart Failure, sponsored by EBR Systems, Inc.. Recruiting at 4 sites in Australia. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by EBR Systems, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Heart Failure with a site in Australia — 25 open to participants now, 41 under way, 9 of them phase 3. Heart Failure · Australia.
Among the 167 studies in Heart Failure with a site in Australia, this one is the 110th largest by planned enrollment of the 135 interventional ones that give a count, is one of 10 that started in 2025, is one of 57 with no phase, reaches primary completion later than 20 of the 40 other live ones, and was the 154th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →25 of the 167 studies in Heart Failure with a site in Australia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, United States, Argentina and 29 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Australia, Austria, Czechia and 10 more countries
Ages 18+
Novo Nordisk A/S · Sites in Australia, United States, Argentina and 24 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Australia, Bulgaria, Croatia and 4 more countries
Ages 18+
Medtronic Cardiac Rhythm and Heart Failure · Sites in Australia, United States, Austria and 12 more countries
Ages 40+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 26 · Phase 3 47 · Phase 4 8
First in 1983; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 350 across the 135 interventional studies, 608 across the 31 observational. Of the 116 that completed or were terminated, 59 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 167 have an industry lead sponsor. The 10 most frequent:
EBR Systems, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
EBR Systems, Inc. has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
10 of the studies in Heart Failure with a site in Australia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT04536870Monash UniversityStatins in Reducing Events in the Elderly (STAREE) Heart Sub-study | 2026-12 |
| NCT03093961Corvia MedicalREDUCE LAP-HFREF TRIAL | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 167 studies in Heart Failure with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Assess the safety and efficacy of the co-implantation of the WiSE CRT System with an intracardiac pacemaker to provide totally leadless CRT.
The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
Single-arm, prospective, multicenter, observational study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with a class I or IIa (1) or (2) indication for implantation of a CRT device according to current available guidelines 1,2,4 (with additional QRS criteria on Class IIa (1)):
Meets criteria for one of the two patient groups
Group A: De novo totally leadless CRT implant in whom the physician believes a totally leadless approach would be beneficial (e.g., wish to avoid lifelong transvenous lead implant, anatomical constraints, history of device infection).
Group B: Upgrade chronic intracardiac pacemaker to CRT
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
.WiSE System therapy ON with Guideline Directed Medical Therapy
Device: WiSE CRT System
The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
Incidence of Device and procedure related complications.
Primary Safety
Time frame: 1 month and 6 months
Bi-Ventricular capture on 12 lead EKG
Performance
Time frame: 1 month and 6 months
Change in ejection fraction (EF) from Baseline
Secondary efficacy 1
Time frame: 6 months
Change in in left ventricular end systolic volume (LVESV)
Secondary efficacy 2
Time frame: 6 months
Change in NYHA class
Secondary efficacy 3
Time frame: 6 months
Change in Six-minute walk test
Secondary efficacy 4
Time frame: 6 months
Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 15 months after the start.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 15 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
EBR Systems, Inc.